Ticagrelor versus clopidogrel dual antiplatelet therapy for unruptured intracranial aneurysms treated with flowdiverter

Archive ouverte

Papaxanthos, Jean | Cagnazzo, Federico | Colmiche, François-Louis | Barreau, Xavier | Radu, Răzvan Alexandru | Gariel, Florent | Derraz, Imad | Gascou, Gregory | Riquelme, Carlos | Ferreira, Ivan | Lefevre, Pierre-Henri | Berge, Jérôme | Costalat, Vincent | Dargazanli, Cyril | Marnat, Gaultier

Edité par CCSD ; Elsevier Masson -

International audience. Background and purpose: Antiplatelet therapy (APT) is a key element limiting the risk of thromboembolic events (TEE) in neuroendovascular procedures, including aneurysm treatment with flowdiverter. Clopidogrel combined with aspirin is the mostly reported dual APT (DAPT). However, resistance phenomenon and intraindividual efficacy fluctuation are identified limitations. In recent years, ticagrelor has been increasingly used in this indication. We compared these two DAPT regimens for intracranial aneurysm treated with flowdiverter.Methods: We conducted a multicentric retrospective study from prospectively maintained databases in two high volume centers extracting consecutive patients presenting unruptured intracranial aneurysm treated with flowdiverter and receiving DAPT (May 2015 to December 2019). Two groups were compared according to their DAPT regimen: "ticagrelor+aspirin" and "clopidogrel+aspirin". Clopidogrel group was systematically checked with platelet test inhibition before endovascular procedure. The primary endpoint was composite, defined as any thrombo-embolic event (TEE) or major hemorrhagic event occurring the first 6 months during and after embolization RESULTS: 260 patients met our inclusion criteria. Baseline patients and aneurysms characteristics were comparable between groups, except for aneurysm location, median size and pre-treatment modified Rankin scale. No significant difference was observed regarding the primary composite outcome: 11.5% (12/104) in the ticagrelor group versus 10.9% (17/156) in the clopidogrel group (p= 1.000). There was also no significant difference in secondary outcomes including TEE (10.5 vs 9.0%; p=0.673), major hemorrhage (0.9 vs 1.2%; p=0.651) and clinical outcome (at least 1-point mRS worsening during follow up: 6.7% vs 8.3%; p=0.813).Conclusion: First-line DAPT with ticagrelor+aspirin seems as safe and effective as clopidogrel+aspirin regimen.

Consulter en ligne

Suggestions

Du même auteur

Comparison of Woven EndoBridge device sizing with conventional measurements and virtual simulation using the Sim&Size software: a multicenter experience

Archive ouverte | Cagnazzo, Federico | CCSD

International audience. Background: Selection of the appropriate device size mandatory during aneurysm treatment with a Woven EndoBridge (WEB). We aimed to investigate if virtual simulation with Sim&Size software ma...

Endovascular therapy with or without intravenous thrombolysis in acute stroke with tandem occlusion

Archive ouverte | Anadani, Mohammad | CCSD

International audience. Background Endovascular therapy (EVT) is effective and safe in patients with tandem occlusion. The benefit of intravenous thrombolysis (IVT) prior to EVT in acute tandem occlusion is debatabl...

European Multicenter Study of ET-COVID-19

Archive ouverte | Cagnazzo, Federico | CCSD

International audience. Background and Purpose: Acute ischemic stroke and large vessel occlusion can be concurrent with the coronavirus disease 2019 (COVID-19) infection. Outcomes after mechanical thrombectomy (MT) ...

Chargement des enrichissements...